Research & Development
Renalytix selects Eversana to expand commercialization of KidneyIntelX test for diabetic kidney disease
The commercialization model developed by the two companies will be launched to primary care providers in parts of the U.S. later in the summer.
May 25, 2023
Renalytix announces review data on kidney disease risk assessment test
A review of the data underscored the effectiveness of KidneyIntelX in identifying patients at greatest risk of decline into kidney failure at the earlier stages, when progression can be slowed.
April 19, 2023
Renalytix highlights study using risk assessment test for diabetic kidney disease
Researchers evaluated the effectiveness of a care management program focused on treating diabetic kidney disease patients in the earliest stages of the disease before significant kidney function loss or other complications have developed.
December 1, 2022
Renalytix to present at American Society of Nephrology Kidney Week
The presentations will include a cost-effectiveness analysis supporting population-based KidneyIntelX testing for Medicare patients, as well as findings from a multiyear study at a major healthcare system highlighting disparities in healthcare access.
October 17, 2022
ADA lowers optimal blood sugar levels for kids
The recommendation was published in Diabetes Care in a review article by Dr. Maria J. Redondo, a pediatric endocrinologist at Texas Children's Hospital and professor at Baylor College of Medicine, as well as Dr. Sarah Lyons, pediatric endocrinologist at Texas Children's and assistant professor at Baylor College of Medicine.
January 14, 2021
Blood test spots diabetes complications early on
The development is significant for patients with type 2 diabetes because if vascular complications, such as heart disease, atherosclerosis, or kidney failure, are detected at an early stage, preventive treatments could be given to avoid severe clinical outcomes down the line.
October 1, 2019
Page 1 of 1